Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31385677 | 1.00 | CA2 (0.61) | CA2ATMKDM4EALDH1A1PPARG | |
| SCHEMBL12170298 | 0.83 | KMT2A (0.51) | CA2ALDH1A1POLBALOX12MEN1 | |
| SCHEMBL12170297 | 0.83 | CYP17A1 (0.45) | CA2KDM4EALDH1A1 | |
| SCHEMBL12170290 | 0.83 | CA2 (0.41) | CA2ATMKDM4EALDH1A1POLB | |
| SCHEMBL12170327 | 0.82 | MAPK1 (0.55) | KDM4EALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12296045 | 0.82 | MEN1 (0.56) | KDM4EALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30038388 | 0.81 | DRD2 (0.50) | CA2ATMKDM4EALDH1A1PPARG | |
| SCHEMBL2557092 | 0.81 | ATM (0.59) | CA2ATMKDM4EALDH1A1PPARG | |
| SCHEMBL9142784 | 0.78 | PTGS2 (0.57) | KDM4EALDH1A1CYP19A1CYP3A4AOC3 | |
| SCHEMBL16641094 | 0.76 | CYP19A1 (0.77) | CA2ATMKDM4EALDH1A1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5403574-A | Evaluation and treatment of the multidrug resistance phenotype | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1995-04-04 | — | — | US | claimed |
| WO-1993000064-A2 | EVALUATION AND TREATMENT OF THE MULTIDRUG RESISTANCE PHENOTYPE | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1993-01-07 | — | — | WO | claimed |
| EP-4615521-A1 | KETO-AMIDE-BASED FIBROBLAST ACTIVATION PROTEIN-TARGETED LIGAND LINKED TO AN IMAGING OR THERAPEUTIC AGENT, COMPOSITIONS AND METHODS OF USE | Purdue Research Foundation (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2025037000-A1 | NOVEL FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND MEDICAL USES THEREOF | UNIVERSITEIT ANTWERPEN (BE) | 2025-02-20 | — | — | WO | disclosed |
| WO-2024102956-A1 | KETO-AMIDE-BASED FIBROBLAST ACTIVATION PROTEIN-TARGETED LIGAND LINKED TO AN IMAGING OR THERAPEUTIC AGENT, COMPOSITIONS AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20100249089-A1 | ABCG2 INHIBITOR | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-0921116-B1 | N-(4-carbamimido-phenyl)-glycine amide derivatives | HOFFMANN LA ROCHE (CH) | 2003-06-18 | — | — | EP | disclosed |
| US-6140353-A | USED AS MEDICAMENTS FOR THE TREATMENT AND/OR PREVENTION OF THROMBOSES, APOPLEXY, CARDIAC INFARCTION, INFLAMMATION AND ARTERIOSCLEROSIS OR AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 2000-10-31 | — | — | US | disclosed |
| EP-0921116-A1 | N-(4-carbamimido-phenyl)-glycine amide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-06-09 | — | — | EP | disclosed |
| US-5403574-A | Evaluation and treatment of the multidrug resistance phenotype | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1995-04-04 | — | — | US | disclosed |
| WO-1993000064-A2 | EVALUATION AND TREATMENT OF THE MULTIDRUG RESISTANCE PHENOTYPE | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1993-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249089-A1 | ABCG2 INHIBITOR | ABCC1, ABCB1, ABCC5 | CA2 3226/4885ATM 456/4885KDM4E 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.